Comparative Study
doi: 10.1093/oxfordjournals.annonc.a058190.
A comparison of CA-549 with CA 15-3 and MCA in patients with metastatic breast cancer
Affiliations
- PMID: 1390307
- DOI: 10.1093/oxfordjournals.annonc.a058190
Item in Clipboard
Comparative Study
A comparison of CA-549 with CA 15-3 and MCA in patients with metastatic breast cancer
Ann Oncol.
1992 Apr.
Free article
Abstract
CA 15-3, MCA, and CA-549 levels were determined in the serum of 56 patients with metastatic breast cancer, all of whom had visceral and/or bone metastases. CA 15-3 was positive in the serum of 37 patients, MCA in the serum of 38 patients, and CA-549 in the serum of 39 patients. All 3 markers were positive in 36 patients, and all 3 were negative in 16 patients. In the serum of 4 patients only 1 or 2 markers were slightly elevated. Thus, the results were identical in 52 of the 56 patients. It is concluded that CA 15-3, MCA, and CA-549 are sensitive markers for advanced breast cancer, and that no advantage can be expected by combining them.
Similar articles
-
Pretreatment concentrations of breast carcinoma antigen (CA 15.3) and mucin-like carcinoma-associated antigen in patients with carcinoma of the breast.Tumour Biol. 1989;10(2):103-8. doi: 10.1159/000217602. Tumour Biol. 1989. PMID: 2734547
-
CA-15.3, TPA and MCA as markers for breast cancer.Eur J Cancer. 1990;26(5):577-80. doi: 10.1016/0277-5379(90)90081-4. Eur J Cancer. 1990. PMID: 2144745
-
Clinical value of a mucin-like carcinoma-associated antigen in monitoring breast cancer patients in comparison with CA 15-3.Eur J Cancer. 1991;27(2):126-31. doi: 10.1016/0277-5379(91)90468-s. Eur J Cancer. 1991. PMID: 1827273
-
T and Tn pancarcinoma markers: autoantigenic adhesion molecules in pathogenesis, prebiopsy carcinoma-detection, and long-term breast carcinoma immunotherapy.Crit Rev Oncog. 1995;6(1):57-85. doi: 10.1615/critrevoncog.v6.i1.50. Crit Rev Oncog. 1995. PMID: 8573608 Review.
-
Tn epitope (N-acetyl-D-galactosamine alpha-O-serine/threonine) density in primary breast carcinoma: a functional predictor of aggressiveness.Mol Immunol. 1989 Jan;26(1):1-5. doi: 10.1016/0161-5890(89)90013-8. Mol Immunol. 1989. PMID: 2467192 Review.
Cited by
-
Relationship between CA 15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease.Br J Cancer. 1997;75(5):698-702. doi: 10.1038/bjc.1997.124. Br J Cancer. 1997. PMID: 9043027 Free PMC article.
-
Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.BMC Cancer. 2006 Nov 20;6:269. doi: 10.1186/1471-2407-6-269. BMC Cancer. 2006. PMID: 17116247 Free PMC article.
-
The correlation of CA15.3 and TPS with tumor course in patients with metastatic breast cancer.J Cancer Res Clin Oncol. 1997;123(2):128-32. doi: 10.1007/BF01269892. J Cancer Res Clin Oncol. 1997. PMID: 9030253 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
